共 50 条
- [41] Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (08) : 1543 - 1554Strober, BruceBlauvelt, AndrewWarren, Richard B.Papp, Kim A.Armstrong, April W.Gordon, Kenneth B.Morita, AkimichiAlexis, Andrew F.Lebwohl, MarkFoley, PeterKisa, Renata M.Colston, ElizabethWang, TaoBanerjee, SubhashisThaci, Diamant
- [42] Deucravacitinib Long-term Efficacy in Patients Originally Randomized to Placebo: 2-Year Results From the POETYK PSO ProgramJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB35 - AB35Lebwohl, MarkWarren, Richard B.Imafuku, ShinichiBagel, JerryArmstrong, April W.Passeron, ThierryColston, ElizabethHippeli, LaurenNapoli, AndrewThaci, DiamantBlauvelt, Andrew
- [43] Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trialsJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025,Armstrong, April W.Lebwohl, MarkWarren, Richard B.Sofen, HowardMorita, AkimichiPaul, CarlePapp, Kim A.Colombo, Matthew J.Scotto, JulieVaile, JohnZhuo, JoeVritzali, EleniBerger, VictoriaSchroeder, GeorgeneBanerjee, SubhashisThaci, DiamantStrober, Bruce
- [44] IMPACT OF ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, DEUCRAVACITINIB, ON PSORIASIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2 TRIALANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1145 - 1146Gottlieb, A. B.Armstrong, A.Merola, J. F.Napoli, A.Nowak, M.Banerjee, S.Lehman, T.Mease, P. J.
- [45] Deucravacitinib, a Selective Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: PASI Body Region and Component Scores in a Phase 3 TrialJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB147 - AB147Tada, YayoiImafuku, ShinichiOkubo, YukariOhtsuki, MamitaroShao, YanqiuColston, ElizabethNapoli, AndrewHippeli, LaurenBanerjee, SubhashisMorita, Akimichi
- [46] Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in psoriasis: Reductions in individual component scores and body regions of the Psoriasis Area and Severity Index in the phase 3 POETYK PSO-1 and PSO-2 trialsJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB41 - AB41Sobell, Jeffrey M.Eyerich, KilianBlauvelt, Andrew
- [47] Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque PsoriasisANNALS OF PHARMACOTHERAPY, 2024, 58 (04) : 416 - 427Truong, Thu MinhPathak, Gaurav N.Singal, AmitTaranto, ViktoriiaRao, Babar K.
- [48] Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in SLE: Efficacy by Baseline Demographics and Disease Characteristics in the Phase 2 PAISLEY TrialARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1367 - 1369Morand, EricArriens, CristinaGeraldino, LauraClarke, Ann E.Pomponi, SamanthaHobar, CoburnWegman, ThomasKoti, RaviBanerjee, SubhashisVan Vollenhoven, Ronald
- [49] Deucravacitinib improves Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis: Results from the phase 3 POETYK PSO-1 and PSO-2 trialsJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB156 - AB156Augustin, MatthiasStrober, BruceArmstrong, April W.Beaumont, JenniferPham, Tan P.Hudgens, StacieZhuo, JoeBecker, BrandonBanerjee, SubhashisKisa, Renata M.Papp, Kim
- [50] Deucravacitinib Improves Dermatology Life Quality Index (DLQI) in Patients with Moderate to Severe Psoriasis: Results fromthe Phase 3 POETYK PSO-1 and PSO-2 TrialsJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 112 - 112Augustin, MatthiasStrober, BruceArmstrong, AprilBeaumont, JenniferPham, TanHudgens, StacieZhuo, JoeBecker, BrandonBanerjee, SubhashisKisa, RenataPapp, Kim